preDiCT

Many drugs fail to reach the market because of side effects on the heart. The principal objective of this proposal is to create an advanced computational technology for in silico assessment of the efficacy and safety of specific drugs [ICT-2007.5.3(c) (3)], i.e. an open environment comprising validated computational models, tools and numerical methods that will enable simulations of drug actions on the electrophysiology of the human heart.

Such simulations will involve modelling of drug interactions at the molecular and cellular level, will extend current technology to enable prediction of the effects of those interactions on the dynamics of the whole heart, and will lead to an understanding of how genetic factors can be used to assess patient-specific risk profiles. This requires a multi-level systems approach, based on multi-scale, multi-physics methods, including computations on adaptive spatial grids and multi-grid time integration. Computations on realistic models at appropriate spatial and temporal scales are currently not feasible, so we will investigate new algorithms and their implementation on high-performance platforms, including a new generation of petaflop computers, to achieve 'faster than real-time' simulation.

These tools form part of the infrastructure required to simulate the physiology of major organ systems, thereby contributing to the goal of creating the Virtual Physiological Human (VPH) [ICT-2007.5.3]. The balanced team in this project, including founders of the Human Physiome Project, has decades of experience in the experimental study and modelling of the electrophysiology and mechanics of the heart, while pharmaceutical industry partners bring deep understanding of the mechanisms of drug actions. The results will demonstrate the value of the VPH initiative to fundamental scientific understanding of the heart, with major economic and clinical impacts through accelerated drug development, approval and use.

For further information, please visit:
http://www.vph-predict.eu

Project co-ordinator:
The Chancellor, Master and Scholars of the University of Oxford

Partners:

  • F. Hoffmann-La Roche AG
  • Szegedi Tudományegyetem
  • Fujitsu Laboratories of Europe Limited
  • Glaxo Smithkline Research and Development
  • Universidad Politécnica de Valencia
  • Centro di Ricerca, Sviluppo e Studi Superiori in Sardegna
  • Novartis Pharma AG
  • Aureus Pharma SA

Timetable: from 06/2008 – to 05/2011

Total cost: € 5.545.692

EC funding: € 4.100.000

Programme Acronym: FP7-ICT

Subprogramme Area: Virtual physiological human

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

NHS and Patients to Benefit from New Par…

IMS MAXIMS and Secure Exchange Solutions have announced a partnership to offer mobile, secure and cost-effective provider-to-provider and provider-to-patient communications to NHS organisations, GP practices and patients.

International Master's in Digital Health

The Master of Science (M.Sc.) in Medical Informatics (MMI) at European Campus Rottal-Inn (ECRI) in Pfarrkirchen - a branch of the Deggendorf University of Applied Sciences (THD - Technische Hochschule...

Digital Medicine: The Opportunities and …

9 - 11 April 2019, Berlin, Germany. Be it preventive healthcare for dementia using intuitive apps, anonymous hospital hygiene inspections using IoT sensors, or VR applications that let hemiplegic patients live...

Highland Marketing Forms Alliance with E…

An alliance between Highland Marketing and Experiential HealthTech will be announced at this year's Digital Health Rewired, with both companies exhibiting from stand B14. Highland Marketing is a full-service marketing...

Google Research Shows How AI can Make Op…

As artificial intelligence continues to evolve, diagnosing disease faster and potentially with greater accuracy than physicians, some have suggested that technology may soon replace tasks that physicians currently perform. But...

Virtual Reality could be Used to Treat A…

Playing games in virtual reality (VR) could be a key tool in treating people with neurological disorders such as autism, schizophrenia and Parkinson's disease. The technology, according to a recent...

Open Call SC1-HCC-02-2019: Support for t…

In the past years several open service platforms for Active and Healthy Ageing domains have been developed, originating from the medical, independent living, and IoT domain. These platforms aim at...

Have an Innovative Digital Health Soluti…

G4A Partnerships are a great opportunity to get your solution in front of Bayer executives and decision makers. All the applications will be reviewed by key stakeholders who have global...

The Moore Blatch Silicon Cup Opens for E…

This year's Moore Blatch Silicon Cup has been launched and is now open for IT companies to enter. The event takes place over 26 - 27 September on the Isle...

MEDICA 2019: Clear Focus on Future Topic…

18 - 21 November 2019, Düsseldorf, Germany. As a result of the final phase of exhibitor registrations for the world’s leading medical trade fare MEDICA 2019 in Düsseldorf, one thing is...

Artificial Intelligence Sheds New Light …

What happens inside a cell when it is activated, changing, or responding to variations in its environment? Researchers from the VIB-UGent Center for Inflammation Research have developed a map of...